Will Novanta (NOVT) Beat Estimates Again in Its Next Earnings Report?
Novanta (NOVT) is predicted to beat its upcoming earnings estimates, continuing a trend from previous quarters. The company's strong history of exceeding earnings, combined with a positive Zacks Earnings ESP of +1.14% and a Zacks Rank #3 (Hold), suggests a high probability of another positive surprise. Novanta is expected to release its next earnings report on February 24, 2026.
Novanta Inc expected to post earnings of 88 cents a share - Earnings Preview
Novanta Inc (NOVT) is projected to report earnings of 88 cents per share. This financial forecast comes from Refinitiv and is part of an earnings preview, indicating an upcoming financial announcement from the company.
American Capital Management Doubles Down on Novanta Stock, According to Latest SEC Filing
American Capital Management Inc. has significantly increased its stake in Novanta (NASDAQ: NOVT) by purchasing an additional 163,005 shares, valued at an estimated $18.56 million, as reported in its latest SEC filing. This acquisition raises Novanta's representation to 2% of the fund's assets under management, with the total NOVT stake now valued at $45.44 million. Despite Novanta's stock seeing only modest long-term growth and a high P/E ratio, American Capital Management's move signals confidence in the company's future, potentially banking on a recovery in the medical and industrial OEM markets.
Strong Earnings Growth Lifted Novanta (NOVT) in Q4
Novanta Inc. (NOVT) demonstrated strong performance in Q4, with Conestoga Capital Advisors highlighting its double-digit growth in the Advanced Surgery business and 17% year-over-year booking growth. The company's ability to exceed profit expectations despite a complex macro environment showcases its resilient and diversified business model. Despite this, Novanta is not considered among the 30 Most Popular Stocks Among Hedge Funds, and some AI stocks are seen as having greater upside potential.
Is It Time To Consider Buying Novanta Inc. (NASDAQ:NOVT)?
Novanta Inc. (NASDAQ:NOVT) recently experienced a significant price hike, nearing its 52-week high, which suggests it is currently overvalued by about 34% according to Simply Wall St's valuation model. Despite the current overvaluation, the company's future earnings are expected to double, indicating an optimistic outlook for long-term investors if a future buying opportunity arises due to its stock volatility. However, potential investors are advised to wait for a price drop, while current shareholders might consider selling high given the stock trading above its intrinsic value.
Novanta Stock Is Roughly Flat This Past Year, So Why Did One Investor Just Bet $45 Million on Shares?
ACK Asset Management recently acquired 375,000 shares of Novanta, a technology company specializing in photonics, vision, and motion control solutions, valued at $44.62 million. This new position represents 5.6% of the fund's 13F assets under management, making it one of their larger allocations. The investment comes despite Novanta's stock being roughly flat over the past year and underperforming the S&P 500, with the investor likely seeing an opportunity in high-precision component suppliers when end markets are volatile.
Herald Investment Management Ltd Purchases Shares of 25,000 Novanta Inc. $NOVT
Herald Investment Management Ltd recently acquired 25,000 shares of Novanta Inc. (NASDAQ:NOVT), valued at approximately $2.5 million, establishing a new position for the fund. This comes as Novanta's institutional ownership stands at nearly 98.35%, despite recent selling by company insiders like the CFO and CEO. Wall Street analysts currently give Novanta a "Hold" rating with a consensus price target of $133.00.
Price-Driven Insight from (NOVT) for Rule-Based Strategy
This article provides a price-driven insight for Novanta Inc. (NASDAQ: NOVT) for rule-based trading strategies. It highlights a strong near-term sentiment but neutral mid and long-term outlook with identified downside risk. The analysis includes various institutional trading strategies like position, momentum, and risk hedging, alongside multi-timeframe signal analysis.
Novanta Stock Is Roughly Flat This Past Year, So Why Did One Investor Just Bet $45 Million on Shares?
ACK Asset Management LLC recently acquired 375,000 shares of Novanta (NASDAQ:NOVT) for approximately $44.62 million, establishing a new position that constitutes 5.6% of the fund’s 13F AUM. Despite Novanta's stock being roughly flat over the past year and underperforming the S&P 500, the investment signals a belief in the company's potential for organic growth, especially as medical and advanced industrial demand is expected to recover. Novanta specializes in photonics, vision, and precision motion components for OEMs in medical and industrial sectors.
Matthijs Glastra Sells 7,500 Shares of Novanta (NASDAQ:NOVT) Stock
Novanta Inc. CEO Matthijs Glastra sold 7,500 shares of the company's stock on February 10th for over $1 million, reducing his stake by 11.56%. This follows other recent sales by Glastra in January. Despite the insider selling, institutional investors like Vanguard and Allspring Global Investments have increased their holdings, and analysts maintain a consensus "Hold" rating for Novanta.
Bessemer Group Inc. Boosts Stock Holdings in Novanta Inc. $NOVT
Bessemer Group Inc. increased its stake in Novanta Inc. (NASDAQ:NOVT) by 24.8% during the third quarter, bringing its total holdings to 222,391 shares valued at approximately $22.27 million. Despite this, company insiders, including CEO Matthijs Glastra and CFO Robert Buckley, sold shares worth over $2 million in the last three months. Analyst ratings for Novanta have shifted towards "Hold," with a consensus price target of $133.00, which is below the stock's recent open price of $141.47.
3 Reasons to Sell NOVT and 1 Stock to Buy Instead
This article suggests selling Novanta Inc. (NOVT) due to lackluster revenue growth, stalled EPS growth, and a dropping free cash flow margin, despite its recent stock performance mirroring the S&P 500. The author argues that its current valuation at 38.1× forward P/E indicates it's overvalued, with too much good news already priced in. Instead, the article recommends exploring other stocks for better growth opportunities, referencing StockStory's "Top 6 Stocks" list which has historically outperformed the market.
Mawer Investment Management Ltd. Has $39.17 Million Stake in Novanta Inc. $NOVT
Mawer Investment Management Ltd. significantly increased its stake in Novanta Inc. by 1,114.5% during Q3, now owning 1.09% of the company, valued at $39.17 million. Novanta exceeded Q3 earnings estimates with $0.87 EPS and $247.8 million in revenue, although its stock has a high trailing PE of 91.5 and recent insider selling indicates a cautious outlook from some executives. The company's average analyst price target is $133.00, with a current market capitalization of $4.81 billion.
Y Intercept Hong Kong Ltd Has $3 Million Holdings in Novanta Inc. $NOVT
Y Intercept Hong Kong Ltd significantly increased its stake in Novanta Inc. (NASDAQ:NOVT) by 86.8% in Q3, now holding 29,970 shares valued at approximately $3.00 million. Despite this, company insiders, including CEO Matthijs Glastra, sold over $2 million worth of shares in the last quarter. Analysts currently maintain a "Hold" rating on Novanta with a consensus target price of $133.00.
The Truth About Novanta Inc: Why Wall Street Is Quietly Loading Up On NOVT
Novanta Inc (NOVT) is a specialized tech company that provides high-precision components and subsystems for medical, industrial, and advanced manufacturing industries. While not a viral meme stock, it's gaining attention from professional investors and long-term funds due to its focus on mega-trends like automation and precision medicine, consistent execution, and stable growth prospects. The article suggests NOVT is a "sleeper pick" for patient investors seeking quality tech and industrial names rather than a quick flip.
Novanta Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing
An insider at Novanta (NOVT) recently sold shares valued at $1,050,000, as detailed in a recent SEC filing. The article also briefly mentions Unity Software's (U.US) fourth-quarter earnings, where its revenue increased 35% year-over-year to $609 million, surpassing analyst estimates. However, Unity reported a quarterly loss of 66 cents per share.
Novanta CEO Glastra sells $1.05 million in shares By Investing.com
Novanta CEO Matthijs Glastra sold 7,500 shares of company stock for $1.05 million on January 21, 2026, executed under a pre-arranged Rule 10b5-1 trading plan. This transaction occurred with Novanta shares trading at $140.00, near $138, and showing a 16.2% year-to-date gain, although InvestingPro analysis suggests the stock might be slightly overvalued with a P/E ratio of 93.9. Glastra retains significant direct and indirect ownership, while the company has also recently updated its financial guidance and announced a public offering of tangible equity units.
(NOVT) as a Liquidity Pulse for Institutional Tactics
This article provides an in-depth analysis of Novanta Inc. (NASDAQ: NOVT) using AI models to suggest institutional trading strategies. It highlights a strong near- and mid-term sentiment but a weak long-term outlook for the stock, indicating elevated downside risk. The analysis includes specific entry, target, and stop-loss points for position trading, momentum breakout, and risk-hedging strategies.
Novanta (NASDAQ:NOVT) CEO Matthijs Glastra Sells 7,500 Shares
Novanta CEO Matthijs Glastra sold 7,500 shares of NOVT stock on January 21st for $1.05 million, reducing his stake by 9.51% to 71,367 shares. This sale, combined with earlier January transactions, totals 14,000 shares sold this month for approximately $1.90 million. Despite the sale, the company recently beat quarterly earnings expectations and issued strong FY2025 guidance, though analysts currently rate the stock as a "Hold" with a consensus price target of $133.00.
Insider Selling: Novanta (NASDAQ:NOVT) CFO Sells 1,423 Shares of Stock
Novanta Inc. (NASDAQ:NOVT) CFO Robert Buckley sold 1,423 shares of the company's stock on January 21st at an average price of $140.14, totaling over $199,000. This transaction reduced his ownership by 1.54%. The company recently beat quarterly earnings estimates and provided optimistic FY2025 guidance, while institutional investors hold a significant majority of the stock.
Novanta CEO Glastra sells $1.05 million in shares By Investing.com
Novanta CEO Matthijs Glastra sold 7,500 company shares worth $1.05 million on January 21, 2026, executed under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Glastra maintains significant direct and indirect ownership in the company. Novanta recently updated its financial guidance for Q4 and full year 2025 and conducted a significant equity offering.
Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, February 24, 2026
Novanta Inc. (Nasdaq: NOVT) is set to release its fourth-quarter 2025 financial results on Tuesday, February 24, 2026. The company will host a conference call on the same day at 8:00 a.m. ET to discuss these results, with access available via phone or a live webcast on their investor relations website. A replay of the webcast will also be available until April 27, 2026.
Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, February 24, 2026
Novanta Inc. (Nasdaq: NOVT) will release its fourth quarter 2025 results on Tuesday, February 24, 2026, and will host a conference call on the same day at 8:00 a.m. ET to discuss these results. Interested parties can access the call via phone or live webcast, with a replay available until April 27, 2026. Novanta is a leading global supplier of core technology solutions for medical, life science, and advanced industrial original equipment manufacturers.
Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, February 24, 2026
Novanta Inc. (Nasdaq: NOVT) has announced that it will release its fourth quarter 2025 results on Tuesday, February 24, 2026. The company will also host a conference call on the same day at 8:00 a.m. ET to discuss these results. Interested parties can access the call via phone or a live webcast on Novanta's investor relations website.
Stocks Showing Improved Relative Strength: Novanta
Novanta (NOVT) has seen its Relative Strength (RS) Rating improve from 61 to 72, indicating stronger market leadership. This exclusive rating by Investor's Business Daily assesses a stock's price performance on a scale of 1 to 99. The improvement in Novanta's RS Rating suggests it is outperforming other stocks in the market.
Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, February 24, 2026
Novanta Inc. (Nasdaq: NOVT) announced it will release its fourth-quarter 2025 financial results on Tuesday, February 24, 2026. The company will host a conference call on the same day at 8:00 a.m. ET to discuss the results, with access available via phone or a live webcast on their investor relations website. A replay of the webcast will be available until April 27, 2026.
Novanta Inc. Launches $550 Million Equity Offering to Boost Strategic Flexibility
Novanta Inc. has announced a proposed public offering of $550 million worth of common stock. The company plans to use the net proceeds from this offering to enhance its strategic flexibility. This move is aimed at strengthening Novanta's financial position and supporting future growth initiatives.
Thames Capital Management LLC Has $5.34 Million Stock Holdings in Novanta Inc. $NOVT
Thames Capital Management LLC reduced its stake in Novanta Inc. (NASDAQ:NOVT) by 16.4% in the third quarter, now holding 53,301 shares valued at approximately $5.34 million. Despite the firm's reduced holding, other institutional investors have recently increased their positions in Novanta. Analysts currently have a "Sell" rating on the stock with an average target price of $133.00, while the CEO recently sold over 6,000 shares.
Matthijs Glastra Sells 6,177 Shares of Novanta (NASDAQ:NOVT) Stock
Novanta CEO Matthijs Glastra sold 6,177 shares of Novanta (NASDAQ:NOVT) stock on January 9th, valued at over $803,000, reducing his stake by 7.26%. Despite the insider selling, Novanta recently beat quarterly earnings estimates and authorized a $200 million stock buyback program. Analysts, however, maintain a cautious "Sell" rating for the stock due to its high P/E ratio and other factors.
Novanta (NASDAQ:NOVT) CEO Sells $42,035.22 in Stock
Novanta CEO Matthijs Glastra sold 323 shares of the company's stock for $42,035.22, reducing his stake by 0.38%. The company recently beat Q3 earnings estimates, issued strong FY2025 guidance, and authorized a $200 million share buyback. Despite a consensus "Sell" rating from analysts, institutional investors hold a significant majority of the stock.
Novanta Inc. Launches $550 Million Equity Offering to Bolster Financial Flexibility
Novanta Inc. has announced a public offering of $550 million in common stock. The company plans to use the net proceeds from this offering for general corporate purposes, which may include strategic acquisitions and managing its capital structure. This move is aimed at enhancing Novanta's financial flexibility and supporting its growth initiatives.
3 Profitable Stocks with Questionable Fundamentals
This article identifies three profitable companies—Novanta (NOVT), Belden (BDC), and Integra LifeSciences (IART)—that, despite their profitability, have questionable fundamental issues making them potentially poor investments. It highlights concerns such as slow revenue growth, stagnating earnings, increasing capital intensity, and high debt, suggesting that investors should look for better opportunities. The piece concludes by recommending StockStory's "Top 5 Strong Momentum Stocks" as an alternative for investors seeking companies with strong growth potential.
Novanta targets $400M advanced surgery revenue by 2030 as new product launches accelerate growth
Novanta is aiming to achieve $400 million in advanced surgery revenue by 2030, leveraging new product introductions and existing technologies. The company plans to grow its surgical business through increased penetration with current customers and expansion into new applications, focusing on areas like robotic surgery and ophthalmic equipment. This strategic goal was highlighted during Novanta's investor day presentation.
Novanta (NASDAQ:NOVT) Stock Price Up 8.8% - Time to Buy?
Novanta (NASDAQ:NOVT) shares increased by 8.8% during Tuesday's trading, despite lower than average trading volume. Analyst sentiment is largely negative, with an average "Sell" rating and a target price of $133.00, following recent downgrades. The company recently beat its last-quarter EPS estimate and authorized a $200 million share buyback, indicating a belief by the board that shares may be undervalued.
Novanta stock sinks 6.7% to start 2026; ISM data and JPM conference loom
Novanta (NOVT) shares fell 6.7% to $111.14 on Friday, the first trading day of 2026, in a low-liquidity session driven by investor focus on interest rates and macro data. Upcoming catalysts include Monday's ISM factory survey, Novanta's Jan. 14 appearance at the J.P. Morgan Healthcare Conference, and expected late-February earnings. The stock's future movement will likely be influenced more by macroeconomic trends than company-specific news.
Novanta stock tumbles 6.6% to start 2026; traders eye Jan. 14 management talks
Novanta Inc. shares fell 6.6% on Friday, the first U.S. trading session of 2026, closing at $111.14. The drop occurred in a holiday-thinned market with lighter volumes as investors anticipate upcoming management presentations on January 14 and key U.S. jobs and inflation data for market direction. Traders are watching the stock's immediate support near $110 and resistance at the $120 level after the recent decline.
Novanta stock dives nearly 6% today as 2026 starts — why NOVT is lagging peers
Novanta Inc. shares dropped almost 6% on the first trading day of 2026, contrasting sharply with gains in its photonics peers. The decline occurred amidst portfolio rebalancing and mixed broader U.S. stock performance. Investors are now looking to upcoming management presentations on January 14 for insights into 2026 demand trends.
(NOVT) Movement as an Input in Quant Signal Sets
This article details a quantitative analysis of Novanta Inc. (NASDAQ: NOVT), highlighting near-term weak sentiment and a mid-channel oscillation pattern. It presents three distinct AI-generated trading strategies with specific entry, target, and stop-loss levels for different risk profiles. The analysis also includes multi-timeframe signal strengths and key support and resistance levels for NOVT.
Allspring Global Investments Holdings LLC Sells 99,712 Shares of Novanta Inc. $NOVT
Allspring Global Investments Holdings LLC reduced its stake in Novanta Inc. by 11.1%, selling 99,712 shares and now holding 795,407 shares valued at $80.19 million. Several research firms have downgraded Novanta to a "Sell" rating, with an average price target of $133.00, despite the company beating recent quarterly earnings estimates and authorizing a $200 million share buyback. Institutional investors collectively own 98.35% of Novanta's stock.
Novanta (NOVT) Valuation After Earnings-Led Selloff and Profitability Concerns
Novanta (NOVT) recently experienced an 11% stock drop after quarterly results beat revenue expectations but missed on EBITDA, raising concerns about its operating discipline. Despite this, analysts project significant earnings growth by 2028, leading to a narrative fair value suggesting the stock is undervalued. However, its high P/E ratio compared to industry averages indicates potential multiple compression risk.
Does Novanta’s (NOVT) Revenue Beat But EBITDA Miss Challenge Its Margin Expansion Narrative?
Novanta (NOVT) recently reported a 1.4% revenue increase, beating analyst expectations, but its EBITDA fell short, raising concerns about its profitability efficiency. This performance, coupled with an 11.4% share price drop, puts focus on margin recovery as a key catalyst, especially given risks from tariffs and relocation costs. Despite a share repurchase authorization, the company's long-term margin expansion narrative faces challenges, making its ability to convert revenue growth into consistent profitability a central investment theme.
How Investors Are Reacting To Novanta (NOVT) After Revenue Beat But EBITDA Miss Raises Efficiency Questions
Novanta (NOVT) reported a revenue beat but an EBITDA miss in its latest quarterly results, raising questions about operational efficiency and profitability. This performance has caused an 11.4% share price drop, shifting investor focus to management's ability to execute cost reduction and regionalization plans. The company's recent US$550 million offering provides financial flexibility for acquisitions and supply chain reconfiguration, which are crucial for its investment narrative.
Insider Sell: Thomas Secor Sells 747 Shares of Novanta Inc (NOVT)
Thomas Secor, a Director at Novanta Inc (NOVT), sold 747 shares of the company on December 22, 2025, leaving him with 0 shares. This transaction is part of a trend for Secor who has sold a total of 1,495 shares over the past year with no purchases. Novanta Inc's stock is currently trading at $120.16, and with a GF Value of $172.66, it is modestly undervalued according to GuruFocus's intrinsic value estimate.
Exchange Traded Concepts LLC Boosts Stake in Novanta Inc. $NOVT
Exchange Traded Concepts LLC has increased its stake in Novanta Inc. (NASDAQ:NOVT) by 22.1%, now owning 178,375 shares valued at approximately $17.86 million. Despite increased institutional investment, analyst sentiment toward Novanta is negative, with a consensus "Sell" rating and a target price of $133. The company reported strong Q3 earnings, beating consensus estimates, and authorized a $200 million share repurchase program.
Responsive Playbooks and the NOVT Inflection
This article provides an in-depth analysis of Novanta Inc. (NASDAQ: NOVT) using AI-generated signals and institutional trading strategies. It highlights a strong near and mid-term sentiment but a weak long-term outlook, with specific entry, target, and stop-loss levels for different trading approaches. The analysis emphasizes risk-reward ratios and multi-timeframe signal analysis to guide traders on potential movements for NOVT.
Congress Asset Management Co. Makes New Investment in Novanta Inc. $NOVT
Congress Asset Management Co. has invested approximately $59.15 million in Novanta Inc. ($NOVT) by purchasing 590,647 shares, making institutional investors own roughly 98.35% of the company. Despite Novanta beating Q3 earnings estimates and authorizing a $200 million share repurchase program, the stock has recently faced downgrades from Weiss and Zacks, resulting in a current market consensus rating of "Sell" with an average target price of $133.00.
Novanta (NASDAQ:NOVT) Rating Lowered to "Strong Sell" at Zacks Research
Zacks Research has downgraded Novanta (NASDAQ:NOVT) from a "hold" to a "strong sell" rating, with Weiss Ratings also cutting their rating to "sell," resulting in an average "Sell" rating and a target price of $133.00 for the company. Despite the downgrades, Novanta recently exceeded Q3 earnings expectations and announced a $200 million share buyback program. The stock experienced a slight price drop and institutional investors currently hold a significant majority of its shares.
Novanta to Present at the CJS Securities 26th Annual New Ideas for the New Year Investor Conference on Wednesday, January 14, 2026
Novanta Inc. announced that its Chief Operating Officer, Chuck Ravetto, will present at the CJS Securities 26th Annual New Ideas for the New Year Investor Conference on Wednesday, January 14, 2026. The conference will be held virtually. Novanta is a global supplier of core technology solutions for medical and advanced industrial equipment manufacturers.
Novanta to Present at the CJS Securities 26th Annual New Ideas for the New Year Investor Conference on Wednesday, January 14, 2026
Novanta Inc. announced its Chief Operating Officer, Chuck Ravetto, will participate in the CJS Securities 26th Annual New Ideas for the New Year Investor Conference virtually on January 14, 2026. Novanta is a leading global supplier of core technology solutions for medical and advanced industrial original equipment manufacturers. The company specializes in precision medicine and manufacturing, medical solutions, and robotics and automation.
Tech supplier Novanta’s COO to appear at virtual investor event
Novanta Inc. announced that its Chief Operating Officer, Chuck Ravetto, will participate in the CJS Securities 26th Annual New Ideas for the New Year Investor Conference virtually on January 14, 2026. Novanta is a global supplier of technology solutions for medical and advanced industrial equipment manufacturers. The company's stock is traded on Nasdaq under the ticker symbol NOVT.
